Clinical trials infusing Bone Marrow Cells (BMCs) into injured hearts have produced measureable improvements in cardiac performance, but were insufficient to improve patient outcomes. Low engraftment rates are cited as probable contributor to limited improvements. To understand the mechanisms that control myocardial engraftment of BMCs following ischemia-reperfusion injury, in isolated-perfused mouse hearts, stop-flow ischemia was followed by variable-duration reperfusion (0-60 min) before addition of labeled syngenic BMCs to the perfusate. After a buffer-only wash, the heart was disaggregated. Retained BMCs (digest) and infused BMCs (aliquot) were compared by flow cytometry for c-kit and CD45 expression to determine the proportion of cell subtypes engrafted versus delivered (selectivity ratio). In these studies, a time-dependent selective retention of c-kit + cells was apparent starting at 30 min of reperfusion, at which time c-kit + /CD45 + BMCs showed a selectivity ratio of 18 ± 2 (versus 2 ± 1 in sham-ischemic controls). To study the underlying mechanism for this selective retention, neutralizing antibodies for P-selectin or L-selectin were infused into the heart preparation and incubated with BMCs prior to BMC infusion. Blocking P-selectin in ischemic hearts ablated selectivity for c-kit + /CD45 + BMCs at 30 min reperfusion (selectivity ratio of 3 ± 1) while selectivity persisted in the presence of L-selectin neutralization (selectivity ratio of 17 ± 2). To corroborate this finding, a parallel plate flow chamber was used to study capture and rolling dynamics of purified c-kit + versus c-kit-BMCs on various selectin molecules. C-kit + BMCs interacted weakly with Lselectin substrates (0.03 ± 0.01% adhered) but adhered strongly to P-selectin (0.28 ± 0.04% adhered). C-kitBMCs showed intermediate binding regardless of substrate (0.18 ± 0.04% adhered on L-selectin versus 0.17 ± 0.04% adhered on P-selectin). Myocardial ischemia-reperfusion stress induces selective engraftment of c-kit + bone marrow progenitor cells via P-selectin activation.
Introduction
Prior dogma asserted that the heart is a terminally differentiated organ with no capacity for generating new cardiomyocytes. However, recent evidence indicates that cardiomyocyte formation occurs throughout life, albeit at low levels [1] . Exploiting fluctuating ambient carbon-14 levels during and after an era of atmospheric nuclear bomb tests, Bergmann et. al. calculated a 1% cardiomyocyte annual turnover rate during early adulthood that eventually declines to 0.45% [2] . Analogous fate-mapping studies in mice likewise suggests low level cardiac myogenesis at baseline that is enhanced following myocardial infarction or sustained pressure overload [3] . In failing human hearts, Kubo et. al. showed that myogenic c-kit + progenitor cells are enriched compared to nonfailing hearts. Most of these c-kit + progenitors co-expressed the pan-leukocyte marker CD45, suggesting a bone marrow origin [4] .
However, the typical scar formation following MI suggests that this native repair response is largely inadequate.
The realization that myocyte repopulation is possible has prompted a series of clinical trials aimed at augmenting the natural repair response in patients with myocardial infarction (MI). Systemic administration of chemokines such as GM-CSF induces increases in circulating bone marrow cells (BMCs) that are believed to be a source of angiogenic and cardiomyogenic progenitors. However, GM-CSF alone has not improved clinical outcomes following MI. In some studies, direct delivery of filtered, autologous bone marrow cells (BMCs) into the coronary arteries or myocardial wall resulted in statistically-significant increases in cardiac performance, but these improvements were also inadequate to improve survival. Low engraftment rates were cited as a primary limitation in some of these studies [5] .
Indeed, follow-up studies determined that 93-98% of bone marrow cells delivered via coronary artery fail to engraft and cannot be detected in the heart within 1 hour [6] [7] .
Although these trials provide encouragement for pursuing progenitor-based therapies, full understanding of the engraftment process and the nature of the engrafted progenitor cells remains underdeveloped. In particular, little is understood about the mechanisms regulating progenitor cell engraftment immediately after myocardial injury or stress. Accordingly, we adapted an isolated-perfused mouse heart (IPMH) model to study BMC engraftment dynamics following ischemia-reperfusion injury (IR-injury). In particular, we employed a heterogenous population of unfractionated BMCs so that ischemia-responsive engraftment would provide unbiased insights into factors affecting this process.
Using this model, we identified a subset of BMCs with injury-dependent selective engraftment into the heart and also a necessary adhesion molecule that facilitates this selectivity. The mechanism for this preferential engraftment was confirmed using an established in vitro model of cell rolling dynamics.
These studies provide new insights into endogenous myocardial repair processes and suggest potential improvements to future therapies for myocardial infarction.
Methods
Isolation of Mouse BMCs . Adult C57BL/6 mice (18-22 g, 10-12 weeks old) were anesthetized with 100 mg/kg ketamine and xylazine, and 1,000 units/kg of heparin was administered IP. Bone marrow was obtained by removing the femurs, and flushing them with sterile PBS over a 40 µm filter. The cells were pelleted by centrifugation and resuspended in lysis buffer (BD Biosciences) for 1 min to lyse red blood cells. Cells were again pelleted and resuspended in 1 mL PBS to remove remaining lysis buffer. Cells were counted using a hemocytometer on an aliquotted sample, and 12±3 million viable (trypan blue exclusion) BMCs were obtained to perform infusions.
Isolated Perfused Mouse Heart for Ischemia-Reperfusion Studies. Following anesthesia and heparization, the heart was rapidly excised, the ascending aorta was cannulated and perfusion was initiated with a modified Krebs bicarbonate buffer, as previously described [8] . Perfusion was restored within 1 min of excision and maintained at 37°C and 2 mL/min. The perfusion solution was aerated with 95% O2, 5% CO2 in order to maintain a pH of 7.4. A side arm in the perfusion line proximal to the heart inflow cannula allowed for entrainment of labeled BMCs along with the oxygenated perfusate.
In all experiments, the perfused hearts underwent 10 min of equilibration time at a flow rate of 2 mL/min at 37°C. After equilibration, the trial cohort underwent no-flow ischemia for 15 minutes (i.e. HEPES+0.5% BSA), until used for the flow chamber experiment. For L-selectin, which has a histidine tag on the C-terminus, the protocol was changed to include an overnight incubation with an antipolyhistidine antibody (R&D Systems, MN), between the protein A/G and selectin coating steps. The apparatus was set up as previously described [10] . + , c-kit -/CD45 -) are similarly represented in both the sham ischemic heart and the bone marrow perfusate aliquot, suggesting that perfusate cell retention in the heart is essentially random (nonselective) in the absence of antecedent ischemia-reperfusion injury (Supp. Fig. 3 ).
Data Analysis for Parallel Plate Flow
Injury-Dependent Engraftment Selectivity for c-kit + /CD45 + Autologous BMCs. In contrast to sham ischemia, stop-flow ischemia for 15 min followed by cell-free and then BMC infusion significantly altered the pattern of retained cells compared with the infused cells. As the representative sample in Fig. 2 shows, c-kit + /CD45 + and c-kit + /CD45 -cells comprise a far greater fraction of the retained cells in IRinjured hearts than in the sham ischemic hearts at a reperfusion duration of 30 min. Based on a series of experiments of this type, the observed proportion of ckit + /CD45 + cells increased from 3±1 percent in sham ischemia heart to 25±7 percent in the stop-flow ischemia heart after reperfusion duration of 30 min (Fig. 3, n=3) . These results confirm that c-kit expression by BMCs is associated with selective retention irrespective of CD45 expression, and that a lack of c-kit expression is associated with a demonstrable reduction in engraftment compared with sham ischemia. We also examined the preferential retention of ckit + BMCs as a function of the duration of cell-free reperfusion prior to initiation of BMC administration.
As shown in Supplemental Table 1 focuses on both c-kit and CD45 immunophenotypes, the selectivity ratios are even higher for the subset of c-kit + cells that are also CD45 + (Fig. 4) . 
Inhibition of P-Selectin or L-selectin in Ischemic Conditions.
In several hearts undergoing 15 min ischemia and 30 min reperfusion, the final 5 min of reperfusion were supplemented with soluble Pselectin or L-selectin neutralizing antibodies (80 µg). Additionally, PKH26GL-labeled BMCs were incubated with the same blocking antibody (5x10 6 BMCs with 30 µg antibody in 0.5 mL) for 15 min prior to being infused to IPMHs. As shown in Fig. 5A , P-selectin inhibition reduced the selectivity ratio for ckit + /CD45 + BMCs in ischemic hearts to 2±1 (compared to 18±2 without neutralization, p=0.002), a result equivalent to unblocked sham ischemia trials. L-selectin inhibition in ischemic hearts produced a ckit + /CD45 + selectivity ratio of 10±4, which was significantly greater than observed in unblocked sham ischemic trials (selectivity ratio of 2±1, p=0.03) and not significantly below unblocked ischemic trials, though a downward trend is observed. For BMC subtypes besides c-kit + /CD45 + , no significant differences were found between any of the 4 protocols (unblocked sham ischemia, unblocked ischemia, or ischemia with either L-selectin or P-selectin blockage). To further confirm the interaction of c-kit + BMCs with endothelial P-selectin, histological sections of a representative ischemic IPMH (15 min ischemia followed by 30 min reperfusion and then BMC infusion) were produced with co-staining for c-kit and endothelial P-selectin. P-selectin is observed only in ischemic, but not sham ischemic, hearts and c-kit + BMCs are frequently found adjacent to regions of P-selectin (Fig. 5B, Fig. 5C , and Supp. Fig. 7 ).
To assess potential coexpression of c-kit and the primary P-selectin ligand (PSGL-1) on BMCs, BMCs were stained with anti-c-kit (AF700-conjugated) and anti-PSGL-1 (PE-conjugated). The odds ratio Fig 8) . Fig. 9 .
Rolling and Adhesion of c-kit+ versus c-kit-BMCs on

Discussion
These studies demonstrate, for the first time, that BMCs expressing the c-kit are preferably retained in the heart following ischemia-reperfusion injury. This selectivity varies in time following the ischemic insult with a delay in the onset of selectivity and greatest selectivity seen after 30 min of reperfusion. The optimum engraftment time of 30 min reperfusion also corresponds with the post-ischemia time required for type 1 activation of the endothelium, during which P-selectin molecules surface from intracellular Weibel-Palade bodies [11] . In contrast, type II activation, which requires transcription, generally requires hours [12] and is likely not responsible for the results we report. Our results are also in excellent temporal agreement with in vivo P-selectin-dependent increases in overall leukocyte rolling following activation of cremaster endothelium conducted by Ley, et. al. [13] . P-selectin is further implicated as the mediating mechanism for this selective retention by our antibody neutralization experiments, which found that Pselectin, but not L-selectin, was required to produce selective engraftment of c-kit + BMCs and by histological demonstration that engrafted c-kit + cells are usually found adjacent to cells expressing Pselectin. Our analysis of the BMCs further demonstrated that c-kit + BMCs are generally positive for PSGL-1, the primary P-selectin ligand in leukocytes, while only about half of c-kit -BMCs express this adhesion molecule. Together, these results indicate that P-selectin/PSGL-1 mediate selective engraftment of c-kit + cells to the heart early after ischemia-reperfusion stress.
Complementing the ex-vivo studies, in vitro exploration of P-and L-selectins, which have been shown to play a part in the inflammatory cell adhesion process [14] , showed a strong selective interaction of c-kit + BMCs with P-selectin. While c-kit + cells demonstrated a statistically-significant decrease in rolling velocity along with a 9-fold increase in firm adhesion from L-to P-selectin, c-kit -BMCs showed nearly identical dynamics regardless of the selectin substrate. As P-selectin is not highly expressed on resting endothelium but is known to surface when the endothelium is activated [15, 16] , the enhanced Pselectin interaction for c-kit + BMCs supports the mechanistic hypothesis that ischemia-induced activation of the coronary endothelium results in P-selectin-mediated selective retention of c-kit + BMCs.
Although the in vivo regenerative capacity of c-kit + BMCs remains controversial, these cells have been shown to differentiate into cardiomyocytes in vivo [17] [18] . Additional angiogenic paracrine signaling effects have been identified for c-kit + BMCs in the injured heart [19] . Thus, the strong retention for these cells in response to injury (selectivity ratio of 18±2) may indicate initiation of a repair response.
Together, these findings provide new insights into the dynamics of cell recruitment to the injured heart while highlighting the utility and versatility of the IPMH model for mechanistic studies focusing on endogenous repair and translational studies aimed at developing or refining new therapeutic strategies.
The features of preferential engraftment of c-kit + BMCs to the heart following ischemia-reperfusion stress in these studies provides clues to the mechanisms of this dynamic process. Most importantly, the preferential recruitment in an IPMH model obviates a requirement for systemic hemodynamic, neural or biochemical triggers for preferential engraftment. However, an auxillary role for such extracardiac factors is not excluded by these studies. Additional factors may be causally related to the selective retention we have described. For example, because ischemia durations of 10 and 30 min. release a burst of reactive oxygen species (ROS) in isolated-perfused rabbit hearts upon reperfusion, the 15 min. ischemia duration utilized in these studies is expected to produce a significant ROS burst that could activate the coronary endothelium [20] . These factors may be causally related to cell engraftment and should be further elucidated to complete our understanding of the mechanistic pathway.
Limitations. Despite the versatility of the IPMH model for studies of cell engraftment, a few limitations deserve mention. For example, we directly infused filtered, labeled bone marrow constituents into the IPMH while the in vivo setting involves an indirect interaction in which marrow-derived cells are released into the circulation and the circulation, in turn, perfuses the myocardium. While our procedure may have allowed some marrow-derived populations greater access of to the heart than occurs in vivo, this realization does not diminish the validity of injury-triggered engraftment cues and preferential engraftment dynamics revealed by these studies. Moreover, the utility of this model is likely greatest for studying early engraftment dynamics before deterioration of contractile performance and edema of the IPMH model reduce its reproducibility and relevance to in vivo dynamics. Additionally, this model is critically dependent on rapid cannulation of the mouse heart since delay will induce ischemic insults that would confound the interpretation of protocol-driven ischemia-reperfusion stress. To address this concern, we routinely abort experiments if the heart cannulation and initiation of perfusion takes more than two minutes. Protocol. Bone marrow perfusate aliquots and heart digests were serially gated as described in Figure 2 (FSC: Forward Scatter, SSC: Side Scatter). A) Aliquot from BMCs infused into a sham ischemic heart (results of corresponding heart digest displayed in graph C below). B) Aliquot from BMCs infused into an ischemic heart (results of corresponding heart digest displayed in graph D below). C-kit + BMCs made up a greater percentage of retained BMCs in ischemia-reperfusion injured hearts than in sham-ischemic hearts despite similar c-kit + representation in infused BMCs. 
Conclusion. Myocardial ischemia-reperfusion
